Yahoo Finance

Citi analyst Patrick Donnelly lowered the firm’s price target on Danaher (DHR) to $285 from $305 and keeps a Buy rating on the shares. Outside of the preannouncements and guidance updates from life science tools and diagnostics names in January, Citi expects key themes to include the cadence and magnitude of the expected recoveries in areas such as China and bioprocessing, the rollout of the China stimulus program, trends within the instrumentation replacement cycle, general biopharma health and its possible impact on clinical trial demand, and the possible effects of the new administration. The firm adjusted numbers for Danaher to reflect currency headwinds.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on DHR:

• Danaher price target lowered to $268 from $278 at Evercore ISI

• Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls

• Scotiabank starts coverage on large cap life science tools trio

• Danaher initiated with a Sector Perform at Scotiabank

• Danaher initiated with a Buy at Guggenheim